These findings revealed that almost 90% of patients treated with Carticel who experienced improvement in knee function at an early follow-up, sustained their improvement for up to almost 10 years.
Leanna Caron, vice president and general manager of Genzyme Biosurgery, the division that manufactures and commercializes Carticel, said: “Long-term durability of Carticel had not been evaluated in the US and there was a critical need to determine if Carticel patients experienced sustained improvement. This study demonstrates both the durability and value of Carticel and leads the field to conclude that a vast majority of this patient population maintained improvement, years following their initial procedure.”